Relationship of the CA-15.3 marker, positivity of hormone receptors and histological diagnosis in breast cancer
Keywords:
BREAST CANCER, CA15.3 MARKER, HORMONE RECEPTORS, HISTOLOGICAL DIAGNOSIS.Abstract
Introduction: breast cancer is a health problem, its metabolic alterations and tumor markers can become a prognostic tool.
Objective: to determine the influence of the modifications and association of tumor marker 15.3, the degree of positivity of estrogen receptors, progestin receptors, HER-2 receptors and histological diagnosis on the clinical characteristics, response to treatment and evolution of patients with breast cancer.
Methods: an analytical, retrospective and cross-sectional observational study was carried out in 45 patients with breast cancer treated at the Third Congress Oncology Center in Pinar del Río, Cuba, in the year 2022.
Results: we found a predominance of patients between 50-59 years old, with overweight and different degrees of obesity, with 60 % of both groups, according to BMI, white skin color, absence of family pathological antecedents, with university education level, with ductal histological diagnosis, tumors between 0.1 - 2.0 cm tumor, time of evolution between one and five years and left breast involvement.
Conclusions: in this study we determined the influence that the modifications and association of the tumor marker 15.3, the degree of positivity of estrogen receptors, progestin receptors, HER-2 receptors and histological diagnosis have on the clinical characteristics, the response to treatment and the evolution of patients with breast cancer.
Downloads
References
1. Osorio Bazar N, Bello Hernández C, Vega Bazar L. Factores de riesgo asociados al cáncer de mama. Rev. Cubana Med Gen Integr [Internet]. 2020 Jun [citado 01/12/2022]; 36(2): e1147. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21252020000200009&lng=es
2. ClèriesR, et al. Exceso de mortalidad en las pacientes con cáncer de mama en estadios precoces en Tarragona y Gerona (España). Gaceta Sanitaria [Internet]. 2020 [Citado 01/12/2022]; 34(4): 356-362. Disponible en: https://doi.org/10.1016/j.gaceta.2018.09.008.
3. Grave de Peralta R, Ramírez Moran Á, Brooks Carballo G. Caracterización epidemiológica del cáncer de mama en el Policlínico “Emilio Daudinot Bueno” en el municipio de Guantánamo. Rev Cubana Med Gen Integr [Internet]. 2022 Jun [citado 25/11/2022]; 38(2): e1763. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21252022000200014&lng=
4. Palmero Picazo J, LassardRosenthal J, Juárez Aguilar L, Medina Núñez C. Cáncer de mama: una visión general. Acta méd. Grupo Ángeles [Internet]. 2021 Sep [citado 27/11/2022]; 19(3): 354-360. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1870-72032021000300354&lng=es
5. Delgado-Díaz N, Heredia-Talledo M, Ramos-Becerra A, Samillán-Jara L, Sánchez-Carranza M, Iglesias-Osores S, et al . Nivel de conocimiento sobre los factores de riesgo y las medidas preventivas del cáncer de mama en estudiantes de ciencias de la salud. Rev. Fac. Med. Hum [Internet]. 2020 Jul [citado 27/11/2022]; 20(3): 412-418. Disponible en:http://revistas.urp.edu.pe/index.php/RFMH/article/view/2900
6. Ministerio de Salud. Anuario Estadístico de Salud [Internet]. La Habana; 2021[citado 26/11/2022]. Disponible en: http://bvscuba.sld.cu/anuario-estadistico-de-cuba/
7. Cabrera Rodríguez C, Cabrera Nogueira G, Márquez Remedio L, Correa Martínez L, Mendive Martínez J. Cáncer de mama en mujeres pinareñas menores de 45 años, serie cronológica de 23 años. Rev Ciencias Médicas [Internet]. 2019 Dic [citado 26/11/2022]; 23(6): 827-835. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-31942019000600827&lng=es.
8.Bonilla-Sepúlveda OA. Marcadores tumorales en cáncer de mama. Revisión sistemática. Ginecol. obstet. Méx [Internet]. 2020 [citado 01/12/2022]; 88(12): 860-869. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0300-90412020001200006&lng=esç
9.Palma S, Cabezas JM. Relación entre índice de masa corporal elevado y variables socioeconómicas en población chilena: un estudio transversal. RevEspNutrHumDiet [Internet]. 2022 Mar [citado 01/12/2022]; 26(1): 52-60. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S2174-51452022000100052&lng=es
10.Citagez B, Yigit B, Capkinoglu E, Yetkin SG. Management of breast cancer during the COVID-19 pandemic. SisliEtfalHastanTipBul [Internet]. 2020 [citado 18/01/2022]; 54(2): 132-135. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326681/
11.Ramírez Carmona W, Padrón González J, Valero Carmona M, Díaz Fabrega B. Factores de riesgo modificables en pacientes con cáncer de mama. RevFinlay [Internet]. 2019 Jun [citado 10/08/2022]; 9(2): 108-17. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S2221-24342019000200108&lng=es
12.González-Longoria B, González Pardo S, López-Muñoz F. Subtipos inmunohistoquímicos y su relación con los aspectos clínico-patológicos e histológicos del cáncer de mama. Medisur [Internet]. 2022 Jun [citado 01/12/2022]; 20(3): 478-486. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1727-897X2022000300478&lng=es
13. Sepúlveda Ó. Ganglio centinela en cáncer de mama: técnica y factores pronósticos. Ginecol. obstet. Méx. [Internet]. 2021 [citado 01/12/2022]; 89(9): 688-695. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0300-90412021000900688&lng=es
14. American Cancer Society. Estado del receptor hormonal del cáncer de seno [Internet]. Cáncer; 2022 [citado 08/11/2021]. Disponible en: https://www.cancer.org/es/cancer/cancer-de-seno/comprension-de-un-diagnostico-de-cancer-de-seno/estado-del-receptor-hormonal-del-cancer-de-seno.html
15. Santiesteban B, Pizarro-Hechavarria R, Hernández-Velázquez F. Antígeno carbohidratado 15.3 en el seguimiento del cáncer de mama. Revista Estudiantil HolCien [Internet]. 2021 [citado 01/12/2022]; 2(2). Disponible en: http://www.revholcien.sld.cu/index.php/holcien/article/view/148
Downloads
Published
How to Cite
Issue
Section
License
Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/
